{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T18:20:27Z","timestamp":1771266027430,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2011,3,11]],"date-time":"2011-03-11T00:00:00Z","timestamp":1299801600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1007\/s10549-011-1429-y","type":"journal-article","created":{"date-parts":[[2011,3,10]],"date-time":"2011-03-10T12:51:32Z","timestamp":1299761492000},"page":"429-438","source":"Crossref","is-referenced-by-count":96,"title":["Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01\u201304) for women with stage II\/III breast cancer"],"prefix":"10.1007","volume":"127","author":[{"given":"R.","family":"Coleman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Woodward","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Cameron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Bell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Dodwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Keane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Gil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Burkinshaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. J.","family":"Houston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. J.","family":"Grieve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. J.","family":"Barrett-Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Thorpe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,3,11]]},"reference":[{"key":"1429_CR1","unstructured":"Ferlay J, Bray F, Pisani P, Parkin DM (2004) GLOBOCAN2002: cancer incidence, mortality and prevalence worldwide. IARCpress, Lyon [06\/01\/2010]. Available from: http:\/\/www-dep.iarc.fr\/"},{"key":"1429_CR2","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/S0140-6736(09)60316-0","volume":"373","author":"JR Benson","year":"2009","unstructured":"Benson JR, Jatoi I, Keisch M, Esteva FJ, Makris A, Jordan VC (2009) Early breast cancer. Lancet 373:1463\u20131479","journal-title":"Lancet"},{"key":"1429_CR3","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1093\/jnci\/djn240","volume":"100","author":"PD Ottewell","year":"2008","unstructured":"Ottewell PD, Monkkonen H, Jones M, Lefley DV, Coleman RE, Holen I (2008) Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst 100:1167\u20131178","journal-title":"J Natl Cancer Inst"},{"key":"1429_CR4","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/ijc.20602","volume":"113","author":"HL Neville-Webbe","year":"2005","unstructured":"Neville-Webbe HL, Rostami-Hodjegan A, Evans CA, Coleman RE, Holen I (2005) Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer 113:364\u2013371","journal-title":"Int J Cancer"},{"key":"1429_CR5","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1056\/NEJMoa0806285","volume":"360","author":"M Gnant","year":"2009","unstructured":"Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Postlberger S, Menzel C et al (2009) Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360:679\u2013691","journal-title":"N Engl J Med"},{"key":"1429_CR6","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/ki.2008.356","volume":"74","author":"MA Perazella","year":"2008","unstructured":"Perazella MA, Markowitz GS (2008) Bisphosphonate nephrotoxicity. Kidney Int 74:1385\u20131393","journal-title":"Kidney Int"},{"key":"1429_CR7","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","volume":"23","author":"A Bamias","year":"2005","unstructured":"Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G et al (2005) Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23:8580\u20138587","journal-title":"J Clin Oncol"},{"key":"1429_CR8","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","volume":"22","author":"S Khosla","year":"2007","unstructured":"Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D et al (2007) Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22:1479\u20131491","journal-title":"J Bone Miner Res"},{"key":"1429_CR9","unstructured":"Cancer therapy evaluation program common toxicity criteria, version 2.0. DCTD, NCI, NIH, DHHS"},{"key":"1429_CR10","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","volume":"61","author":"RE Marx","year":"2003","unstructured":"Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61:1115\u20131117","journal-title":"J Oral Maxillofac Surg"},{"issue":"Supplement 1","key":"1429_CR11","first-page":"2","volume":"67","author":"SL Ruggiero","year":"2009","unstructured":"Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B (2009) American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update. J Oral Maxillofac Surg 67(Supplement 1):2\u201312","journal-title":"J Oral Maxillofac Surg"},{"key":"1429_CR12","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1200\/JCO.2005.05.3744","volume":"25","author":"A Brufsky","year":"2007","unstructured":"Brufsky A, Harker WG, Beck JT, Carroll R, Tan-Chiu E, Seidler C et al (2007) Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 25:829\u2013836","journal-title":"J Clin Oncol"},{"key":"1429_CR13","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1093\/annonc\/mdq217","volume":"21","author":"H Eidtmann","year":"2010","unstructured":"Eidtmann H, de Boer R, Bundred N, Llombart A, Davidson N, Neven P, von Minckwitz G, Miller J, Schenk N, Coleman R (2010) Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST study. Ann Oncol 21:2188\u20132194","journal-title":"Ann Oncol"},{"issue":"suppl","key":"1429_CR14","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S1359-6349(07)70770-X","volume":"5","author":"N Schenk","year":"2007","unstructured":"Schenk N, Lombart A, Frassoladti A, Neven P, Jerusalem G, Deleu I et al (2007) The E-ZO-FAST trial: zoledronic acid (ZOL) effectively inhibits aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (EBC) receiving adjuvant letrozole (Let). Eur J Cancer 5(suppl):186\u2013187 9abs","journal-title":"Eur J Cancer"},{"issue":"1","key":"1429_CR15","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1517\/14740338.2011.540387","volume":"10","author":"R Coleman","year":"2011","unstructured":"Coleman R, Burkinshaw R, Winter M, Neville-Webbe H, Lester J, Woodward E, Brown J (2011) Zoledronic acid. Expert Opin Drug Saf 10(1):133\u2013145","journal-title":"Expert Opin Drug Saf"},{"key":"1429_CR16","unstructured":"Stopeck A (2009) A comparison of denosumab versus zoledronic acid on the incidence of skeletal-related events in breast cancer patients with bone metastases. Cancer Research, 69(24): San Antonio breast cancer conference presentation Abs 22"},{"key":"1429_CR17","doi-asserted-by":"crossref","unstructured":"Guarneri V, Miles D, Robert N, Di\u00e9ras V, Glaspy J, Smith I et al (2010) Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat 122:181\u2013188","DOI":"10.1007\/s10549-010-0866-3"},{"key":"1429_CR18","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ygyno.2008.11.029","volume":"112","author":"T Fehm","year":"2009","unstructured":"Fehm T, Beck V, Banys M, Lipp HP, Hairass M, Reinert S et al (2009) Bisphosphonate-induced osteonecrosis of the jaw (ONJ): incidence and risk factors in patients with breast cancer and gynaecological malignancies. Gynecol Oncol 112:605\u2013609","journal-title":"Gynecol Oncol"},{"key":"1429_CR19","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1002\/cncr.24119","volume":"115","author":"C Walter","year":"2009","unstructured":"Walter C, Al-Nawas B, Bois Ad, Buch L, Harter P, Gr\u00f6tz KA (2009) Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients. Cancer 115:1631\u20131637","journal-title":"Cancer"},{"key":"1429_CR20","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/sj.bjc.6604382","volume":"98","author":"RE Coleman","year":"2008","unstructured":"Coleman RE (2008) Risks and benefits of bisphosphonates. Br J Cancer 98:1736\u20131740","journal-title":"Br J Cancer"},{"issue":"7","key":"1429_CR21","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1345\/aph.1E589","volume":"39","author":"A Munier","year":"2005","unstructured":"Munier A, Gras V, Andrejak M, Bernard N, Jean-Pastor M-J, Gautier S et al (2005) Zoledronic acid and renal toxicity: data from French adverse effect reporting database. Ann Pharmacother 39(7):1194\u20131197","journal-title":"Ann Pharmacother"},{"key":"1429_CR22","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809\u20131822","journal-title":"N Engl J Med"},{"key":"1429_CR23","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/BOR.0b013e32832ca433","volume":"21","author":"DH Solomon","year":"2009","unstructured":"Solomon DH, Rekedal L, Cadarette SM (2009) Osteoporosis treatments and adverse events. Curr Opin Rheumatol 21:363\u2013368","journal-title":"Curr Opin Rheumatol"},{"key":"1429_CR24","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.amjcard.2008.11.037","volume":"103","author":"TJ Bunch","year":"2009","unstructured":"Bunch TJ, Anderson JL, May HT, Muhlestein JB, Horne BD, Crandall BG et al (2009) Relation of bisphosphonate therapies and risk of developing atrial fibrillation. Am J Cardiol 103:824\u2013828","journal-title":"Am J Cardiol"},{"issue":"33","key":"1429_CR25","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1200\/JCO.2010.28.7524","volume":"28","author":"GS Wilkinson","year":"2010","unstructured":"Wilkinson GS, Baillargeon J, Kuo YF, Freeman JL, Goodwin JS (2010) Atrial fibrillation and stroke associated with intravenous bisphosphonate therapy in older patients with cancer. J Clin Oncol 28(33):4898\u20134905","journal-title":"J Clin Oncol"},{"key":"1429_CR26","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/(SICI)1096-9926(199908)60:2<68::AID-TERA10>3.0.CO;2-H","volume":"60","author":"N Patlas","year":"1999","unstructured":"Patlas N, Golomb G, Yaffe P, Pinto T, Breuer E, Ornoy A (1999) Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats. Teratology 60:68\u201373","journal-title":"Teratology"},{"key":"1429_CR27","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1359\/JBMR.040711","volume":"19","author":"CF Munns","year":"2004","unstructured":"Munns CF, Rauch F, Ward L, Glorieux FH (2004) Maternal and fetal outcome after long-term pamidronate treatment before conception: a report of two cases. J Bone Miner Res 19:1742\u20131745","journal-title":"J Bone Miner Res"},{"key":"1429_CR28","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0936-6555(05)80667-3","volume":"8","author":"TM Illidge","year":"1996","unstructured":"Illidge TM, Hussey M, Godden CW (1996) Malignant hypercalcaemia in pregnancy and antenatal administration of intravenous pamidronate. Clin Oncol 8:257\u2013258","journal-title":"Clin Oncol"},{"key":"1429_CR29","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.bone.2008.11.001","volume":"44","author":"S Levy","year":"2009","unstructured":"Levy S, Fayez I, Taguchi N, Han J-Y, Aiello J, Matsui D et al (2009) Pregnancy outcome following in utero exposure to bisphosphonates. Bone 44:428\u2013430","journal-title":"Bone"},{"key":"1429_CR30","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.reprotox.2006.05.009","volume":"22","author":"A Ornoy","year":"2006","unstructured":"Ornoy A, Wajnberg R, Diav-Citrin O (2006) The outcome of pregnancy following pre-pregnancy or early pregnancy alendronate treatment. Reprod Toxicol 22:578\u2013579","journal-title":"Reprod Toxicol"},{"key":"1429_CR31","doi-asserted-by":"crossref","first-page":"5406","DOI":"10.1158\/1078-0432.CCR-07-0247","volume":"13","author":"JE Brown","year":"2007","unstructured":"Brown JE, Ellis SP, Lester JE, Gutcher S, Khanna T, Purohit OP et al (2007) Prolonged efficacy of a single dose of the bisphosphonate zoledronic acid. Clin Cancer Res 13:5406\u20135410","journal-title":"Clin Cancer Res"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-011-1429-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-011-1429-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-011-1429-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,9]],"date-time":"2019-06-09T05:50:56Z","timestamp":1560059456000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-011-1429-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,11]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["1429"],"URL":"https:\/\/doi.org\/10.1007\/s10549-011-1429-y","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3,11]]}}}